Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial

摘要

Background andObjectiveClinical practice guidelines recommend antipsychotic monotherapy, including oral and long-acting formulations, in the treatment of schizophrenia. This open-label, randomized, controlled trial aimed to evaluate the efficacy and tolerability in patients with schizophrenia of once-monthly long-acting paliperidone palmitate (PP1M) compared with oral paliperidone extended release (ER), with a particular focus on satisfaction, subjective well-being, and service engagement.MethodsSeventy-two consecutive outpatients with schizophrenia (DSM-5) were randomly assigned for 6months to: (1) PP1M (50-150mg equivalent) or (2) paliperidone ER (6-12mg/day). Participants were assessed at baseline and after 6months with the Treatment Satisfaction Questionnaire for Medication (TSQM); the Subjective Well-being under Neuroleptics Scale (SWN-K); the Service Engagement Scale (SES); the Clinical Global Impression-Schizophrenia (CGI-SCH); and the Personal and Social Performance (PSP) score. ANOVA repeated measures was performed. Intention-to-treat analysis with last observation carried forward was conducted.ResultsWe found a significant within-subjects effect (trial duration) for all rating scale except for cognitive symptoms and the TSQM domain side effects. A significant effect between subjects (treatment modality) was found for the CGI negative symptoms, the TSQM domains overall satisfaction and convenience, and the SES. There were seven drop-outs (9.7%): twi due to hyperprolactinemia and five for lack of compliance.ConclusionsSignificant differences between the two formulations were found. PP1M was superior to paliperidone ER on global treatment satisfaction and convenience, on service engagement, and in reducing negative symptoms.The trial was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR) with the code: ACTRN12618001113246.